Mesothelioma Articles

FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer
February 9, 2006

Alternative Title

Phase I Study of FR901228 and Flavopiridol in Patients With Advanced Primary Lung or Esophageal Cancer, Malignant Pleural Mesothelioma, or Lung or Pleural Metastases

Basic Trial Information

Special Category: NIH Clinical Center trial

Trial Description

Purpose:

Drugs used in chemotherapy, such as FR901228 and flavopiridol, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving FR901228 together with flavopiridol may kill more tumor cells.

This phase I trial is studying the side effects and best dose of FR901228 when given together with flavopiridol in treating patients with advanced lung, esophageal, or pleural cancer.

Eligibility:

Eligibility criteria include the following:

    · At least 18 years old
    · At least 1 month since biological therapy or chemotherapy for this cancer

Final eligibility for a clinical trial is determined by the health professionals conducting the trial. For more details about the eligibility requirements for this trial and the treatment or intervention, refer to the Health Professional version of the trial summary.

Treatment/Intervention:

Patients will receive a 4-hour infusion of FR901228 and a 72-hour continuous infusion of flavopiridol in weeks 1 and 3. Treatment may be repeated every 4 weeks for as long as benefit is shown.

Important:

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations:

NCI - Center for Cancer Research

David S. Schrump, MD, Protocol chair
     Ph: 301-451-1233
     Email: david_schrump@nih.gov

Trial Sites and Contacts:

U.S.A.

Maryland

    Bethesda

    NCI - Center for Cancer Research

    Clinical Trials Office - NCI - Center for Cancer Research
    Ph: 888-624-1937

    Dao Nguyen
    Ph: 301-451-1233

    Tricia Kunst, RN
    Ph: 301-451-1233
    Email: tricia_kunst@nih.gov

    Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

    NCI Clinical Studies Support
    Ph: 888-NCI-1937

Related Information

Web site for additional information - http://bethesdatrials.cancer.gov/patients/search_detail.asp?ProtocolID=NCI-05-C-0010

***Source: http://www.cancer.gov/clinicaltrials***

MIRG.org 1-888-802-6376 e-mail

www.MIRG.org • Site Map • About Us • Contact Us • Links • Disclaimer